30 / 60
28
POSTERS
| PROGRAMME & EXHIBITION GUIDE
Influence on toxicity mucositis depending on contouring the oral cavity: our
experience
J. Marin (Spain), M.A. Garcia, I. Prieto, A.M. Perez
PO-093
Can the mean dose delivered to the superficial parotid lobe predict xerostomia
following RT in HNC?
D. Nevens (Belgium), S. Nuyts
PO-094
An evaluation of IMPT versus rotational IMRT for nasopharyngeal carcinoma
T. Williams (United Kingdom), P. Sanghera, A. Hartley, G. Heyes, A. Dumbill,
A. Chalkley, Y. Roussakis, J. Cashmore
PO-095
Cetuximab(CET), 5-FU and cisplatin or carboplatin (CA) versus CET, paclitaxel and
CA in metastatic head and neck cancer
S. Friesland (Sweden), L. Specht, H. Haugen, K. Söderström
PO-096
Poster
BIOLOGY, HPV, IMMUNOLOGY ANDMOLECULAR TARGETING
Genome-scale methylation assessment did not identify prognostic biomarkers in
oral tongue carcinomas
A. Lim (Australia), N. Wong, R. Pidsley, E. Zontenko, J. Corry, A. Dobrovic,
B. Solomon, D. Rischin, S. Clark
PO-097
A re-evaluation of late mucosal toxicity: evidence for a mixed consequential-late
effect?
A. Hartley, P. Sanghera, J. Glaholm, C. McConkey, C. Boon (United Kingdom), S. Meade
PO-098
Combination of mTOR targeting with cetuximab, and chemotherapy: a preclinical
study on head and neck cancer
A. Bozec (France), N. Ebran, A. Sudaka, M.C. Etinne-Grimaldi, F. Penaud-Llorca,
G. Milano
PO-099
E6 viral protein ratio correlates with outcomes in human papillomavirus related
oropharyngeal cancer
A. Hong (Australia), X. Zhang, D. Jones, M. Zhang, C.S. Lee, J.G. Lyons, A.S. Veillard,
B. Rose
PO-100